DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



TAP-patients With Robotic Assisted Lap Prostatectomy

Information source: Pacira Pharmaceuticals, Inc
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain

Intervention: fentanyl (Drug); fentanyl, sufentanil (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Pacira Pharmaceuticals, Inc

Official(s) and/or principal investigator(s):
Andrew Sternlicht, MD, Principal Investigator, Affiliation: Steward St. Elizabeth's

Overall contact:
Jocelyn Wise, Email: jocelyn.wise@steward.org

Summary

The study of the analgesic affect when infiltrated into the TAP for men undergoing prostatectomy.

Clinical Details

Official title: Evaluation of the Safety and Efficacy of EXPAREL When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) for Prolonged Postsurgical Analgesia in Subjects Undergoing Robot-assisted Laparoscopic Prostatectomy

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The duration of abdominal analgesia from infiltration into the TAP

Secondary outcome: assess the volume of EXPAREL infiltrated into the TAP influences the duration of analgesia

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- male subjects, aged 18-75

- ASA physical status 1-3

- Undergoing robot-assisted laparoscopic prostatectomy performed by a single surgeon

(Ingolf Tuerk, MD)

- Subjects must be physically and mentally able to participate in the study and

complete all study assessments.

- Subjects must be able to give fully informed consent to participate in this study

after demonstrating a good understanding of the risks and benefits of the TAP infiltration.

Exclusion Criteria:

- Demonstrated hypersensitivity or idiosyncratic reactions to amide-type local

anesthetics.

- Inability to tolerate oxycodone with acetaminophen (e. g. Percocet)

- Any subject whose anatomy or surgical procedure in the opinion of the Investigator

might preclude the potential successful performance of a TAP.

- Any subject who in the opinion of the Investigator might be harmed or be a poor

candidate for participation in the study.

- Subjects who have received any investigational drug within 30 days prior to study

drug administration or planned administration of another investigational product or procedure during their participation in this study.

Locations and Contacts

Jocelyn Wise, Email: jocelyn.wise@steward.org

Steward St. Elizabeth's, Brighton, Massachusetts 02135, United States; Recruiting
Jocelyn Wise, Email: jocelyn.wise@steward.org
Max Shapiro, Email: max.shapiro@steward.org
Andrew Sternlicht, MD, Principal Investigator
Additional Information

Starting date: March 2012
Last updated: April 19, 2012

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014